N-but-E-enyl norbuprenorphine and methods of use

Abstract

The present invention provides compound having the structure: and pharmaceutically acceptable salts or derivatives thereof, as well as compositions including such compounds. The invention also provides methods of (1) preventing pain, (2) treating pain, (3) inducing sedation, (4) treating opiate addiction, (5) treating opiate withdrawal (abstinence syndrome) and/or (6) treating cough in a patient in need thereof by administering a compound or composition of the invention.

1 . A method of stimulating μ opiate receptors in a patient in need thereof, said method comprising administering a μ opiate receptor agonizing effective amount of a compound having the structure:  
       
         
           
           
               
               
           
         
       
       a pharmaceutically acceptable salt, ether derivative, ester derivative, acid derivative, aqueous, enantiomer, diastereomer, racemate, polymorph, or solvate thereof to said patient.  
     
     
         2 . A method as defined in  claim 1 , wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, and buccal administration.  
     
     
         3 . A method as defined in  claim 1 , wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml of said compound.  
     
     
         4 . A method of preventing pain in a patient in need thereof, said method comprising administering an analgesic effective amount of a composition as defined in  claim 1  to said patient.  
     
     
         5 . A method as defined in  claim 4 , wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, epidural, intrathecal, and buccal administration.  
     
     
         6 . A method as defined in  claim 4 , wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.  
     
     
         7 . A method of treating pain in a patient in need thereof, said method comprising administering an analgesic effective amount of a composition as defined in  claim 1  to said patient.  
     
     
         8 . A method as defined in  claim 7 , wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, and buccal administration.  
     
     
         9 . A method as defined in  claim 7 , wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.  
     
     
         10 . A method as defined in  claim 7 , wherein said pain is moderate or severe.  
     
     
         11 . A method of sedating a patient in need thereof, said method comprising administering a sedating effective amount of a composition as defined in  claim 1  to said patient.  
     
     
         12 . A method as defined in  claim 11 , wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, epidural, intrathecal, and buccal administration.  
     
     
         13 . A method as defined in  claim 11 , wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.  
     
     
         14 . A method of treating cough in a patient in need thereof comprising administering an anti-tussive effective amount of a composition as defined in  claim 1  to said patient.  
     
     
         15 . A method as defined in  claim 14 , wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of from about 20 pg/ml to about 10 ng/ml to said patient.  
     
     
         16 . A method of treating opioid withdrawal (abstinence syndrome) in a patient in need thereof comprising administering an opioid withdrawal-relieving effective amount of a composition as defined in  claim 1  to said patient.  
     
     
         17 . A method as defined in  claim 16 , wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.  
     
     
         18 . A method of treating opioid addiction in a patient in need thereof comprising administering an addiction-relieving effective amount of a composition as defined in  claim 1  to said patient.  
     
     
         19 . A method as defined in  claim 18 , wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.  
     
     
         20 . A kit comprising a composition as defined in  claim 1 , and a container, label, and instructions for use.